Evidence map›Paper›PMID 39926228›Full record

ArticleRSC advances2025

Ultrasound-assisted synthesis of new bisphosphonate-betulin conjugates and preliminary evaluation of their cytotoxic activity.

Dominika Kozicka, Małgorzata Krześniak, Mirosława Grymel, Jakub Adamek, Barbara Łasut-Szyszka, Tomasz Cichoń, Anna Kuźnik

Abstract read
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Synthesis of Amino-Pharmaceuticals (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dominika KozickaDepartment of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Silesian University of Technology B. Krzywoustego 4 44-100 Gliwice Poland anna.kuznik@polsl.pl.ORCID https://orcid.org/0000-0001-9418-1348
Małgorzata KrześniakCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch Wybrzeże Armii Krajowej 15 44-102 Gliwice Poland.ORCID https://orcid.org/0000-0003-3249-2372
Mirosława GrymelDepartment of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Silesian University of Technology B. Krzywoustego 4 44-100 Gliwice Poland anna.kuznik@polsl.pl.ORCID https://orcid.org/0000-0003-4649-1194
Jakub AdamekDepartment of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Silesian University of Technology B. Krzywoustego 4 44-100 Gliwice Poland anna.kuznik@polsl.pl.ORCID https://orcid.org/0000-0002-2960-6247
Barbara Łasut-SzyszkaCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch Wybrzeże Armii Krajowej 15 44-102 Gliwice Poland.ORCID https://orcid.org/0000-0001-8458-6077
Tomasz CichońCenter for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch Wybrzeże Armii Krajowej 15 44-102 Gliwice Poland.
Anna KuźnikDepartment of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Silesian University of Technology B. Krzywoustego 4 44-100 Gliwice Poland anna.kuznik@polsl.pl.ORCID https://orcid.org/0000-0002-0801-7435

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bisphosphonates (BPs) are a well-established group of drugs that have been used for decades in the prevention and treatment of osteoporosis and cancer treatment-induced bone loss. Their unique properties such as high bone affinity, enzymatic stability as well as a multidirectional biological activity prompt the creation of BP conjugates. In this study, we designed and synthesized three new bisphosphonate conjugates with betulin, a natural product with a high safety profile and a broad spectrum of biological activity. The designed conjugates differed in the type of linker used and the number of bisphosphonate moieties attached (mono- or disubstituted derivatives). The proposed method for their synthesis proceeds under mild reaction conditions and gives good yields of products. In addition, as we have shown, the reaction can be assisted by ultrasound, which significantly reduced the reaction time (from 48 hours to 2 hours) and improved the overall product yield (up to 92%). The cytotoxicity of the new conjugates was evaluated against osteosarcoma (U-2 OS), lung adenocarcinoma (A549) and gastric adenocarcinoma (AGS) cell lines. The results of preliminary biological studies showed that the obtained conjugates had improved solubility compared to that of betulin and exhibited a cytotoxic effect on all three tested cell lines at the micromolar level. The betulin analog having two bisphosphonate groups 6 demonstrated the highest cytotoxic activity against tested cell lines (IC50 between 5.16 and 6.21 μM).

Identifiers

PMID39926228
PMCPMC11800102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.